期刊
ECLINICALMEDICINE
卷 55, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.eclinm.2022.101753
关键词
Objective response rates; Placebo; RCT
This study provides a pooled placebo response rate from drug trials in advanced solid tumors. The results show that about 1% of patients can expect to achieve some response even in the absence of treatment, but complete regression without treatment is extremely rare, almost zero percent. This information is important for patients in their treatment decisions and regulators evaluating the efficacy of cancer drugs based on response rates alone.
Background Spontaneous regression of advanced solid tumors is infrequent but may occur. Quantifying response rates from placebo in cancer drug trials may provide important information for physicians, patients, and regulators. We aimed to provide a pooled placebo response rate from drug trials in advanced solid tumors. Methods We pooled the overall response rate (ORR), complete response rate (CR) and partial response rates (PR) in the placebo arm of placebo-controlled randomized controlled trials (RCTs) of cancer drugs for advanced solid tumors published during 2015-2021 using random-effects model. Findings 45 phase 3 RCTs including 5684 patients on placebo met our inclusion criteria and formed the study cohort. The pooled overall ORR, CR and PR rates in the placebo arm were 1% (95% CI, 0%-2%), 0% (95% CI, 0%-0%), and 1% (95% CI, 0%-2%) respectively. Higher placebo responses were observed in prostate cancer and sarcoma trials. Interpretation Overall, 1% patients with advanced solid tumors can expect to achieve some response even in absence of treatment. However, complete regression without treatment is extremely rare, almost zero percent. This information will be helpful to patients in their decisions, as well as regulators in evaluating cancer drugs' efficacy based on response rates alone. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据